Could a COVID-19 vaccine be closer than we thought?  | The Times of India


Dr Gagandeep Kang, who is a Medical Scientist and Former Chair Member of ICMR Panel on COVID drugs and vaccines feels that right now, while major hurdles of the vaccine trials have been cleared, the focus should be on structural distribution and administration- which will deem whether a vaccine truly workable or not.

“It takes time to make a vaccine and the reason why vaccine manufacturers are now trying to buy facilities, book time at the manufacturing facilities, is because they want to be able to make the vaccine even before it is proven safe and effective…That is the fastest way to get to the market but the whole process of regulation takes time. It will take time to review the dossiers, it will take time to get the vaccine licensed, and once the vaccine is licensed we have to think about the logistics of distribution… You need something that fits in with your cold chain infrastructure, you need to be able to buy the vaccine, you need to land the vaccine, you need to distribute the vaccine, you need to train staff in how to give the vaccine.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

error

Enjoy this blog? Please spread the word :)

Follow by Email
LinkedIn
Share
Instagram